Contains information from HSA Listing of Registered Therapeutic Products accessed on 8 October 2026 from data.gov.sg, under Singapore Open Data Licence 1.0: https://data.gov.sg/open-data-licence

Licence: Singapore Open Data Licence 1.0 · Added 8 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Lisdexamfetamine dimesylate
Strength: 50.0 mg
Dosage form: capsule
Route: oral
Register: Singapore (HSA)
Status: Authorised
Status in the register: Registered
Authorised: 1 Nov 2019
Registration: SIN15843P
Marketing authorisation holder: Takeda Pharmaceuticals (Asia Pacific) Pte. LTD.
Manufacturer: Patheon Pharmaceuticals Inc. (Bulk Production) / Takeda GmbH, UNITED STATES / GERMANY
ATC code: N06BA12
Group: Nervous system
Supply: Prescription Only

VYVANSE CAPSULES 40 mgLisdexamfetamine dimesylate · 40.0 mg · capsuleSingapore

VYVANSE CAPSULES 60 mgLisdexamfetamine dimesylate · 60.0 mg · capsuleSingapore

VYVANSE CAPSULES 70 mgLisdexamfetamine dimesylate · 70.0 mg · capsuleSingapore